Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Jump-starting the T cell response in established tumors.

bioRxiv : the preprint server for biology·2026
Same author

Predictive capacity of mismatch repair status in the use of immune checkpoint inhibitors for the treatment of aggressive pituitary tumors and pituitary carcinomas: An illustrative case report and literature review.

Surgical neurology international·2026
Same author

Cultured <i>ex vivo</i> human brain tissue maintains cell-type transcriptional identities.

Brain communications·2026
Same author

Dual phagocytosis-checkpoint blockade revitalizes immune surveillance in mouse models of glioblastoma.

Nature communications·2026
Same author

Postoperative Seizure in Patients with Malignant Glioma Undergoing Tumor Resection with Intraoperative Mapping: Risk Factors, Management Strategies, and the Utility of Bayesian Analysis in a Case-Control Cohort.

Research square·2026
Same author

Microbial signals in primary and metastatic brain tumors.

Nature medicine·2025

Related Experiment Video

Updated: Mar 1, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K

Beyond Alkylating Agents for Gliomas: Quo Vadimus?

Vinay K Puduvalli1, Rekha Chaudhary1, Samuel G McClugage1

  • 1From The Ohio State University Comprehensive Cancer Center, Columbus, OH; University of Cincinnati, Cincinnati, OH; University of Alabama at Birmingham, Birmingham, AL.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|June 1, 2017
PubMed
Summary

Novel therapies like immunotherapy and metabolic targeting show promise for treating gliomas, offering new hope where traditional treatments have failed. These approaches aim to overcome challenges like tumor heterogeneity and the blood-brain barrier for better patient outcomes.

More Related Videos

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.5K
Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
04:46

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

2.4K

Related Experiment Videos

Last Updated: Mar 1, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.5K
Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
04:46

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

2.4K

Area of Science:

  • Neuro-oncology
  • Cancer Therapy
  • Molecular Biology

Background:

  • Standard glioma treatments (surgery, radiation, chemotherapy) show limited efficacy.
  • Tumor heterogeneity, resistance, and blood-brain barrier impede treatment success.
  • Genetic and epigenetic alterations specific to gliomas are known.

Purpose of the Study:

  • To review novel therapeutic strategies for gliomas.
  • To explore emerging treatments beyond conventional approaches.
  • To highlight the potential of new therapies for improved patient outcomes.

Main Methods:

  • Review of recent advances in glioma treatment research.
  • Analysis of immunotherapeutic approaches (vaccines, checkpoint blockade, CAR-T).
  • Evaluation of targeted therapies (signaling hubs, metabolic pathways, biologic agents).

Main Results:

  • Immunotherapy and targeted pathway inhibition are under active clinical investigation.
  • Novel agents aim to overcome limitations of conventional therapies.
  • Growing interest in evidence-based alternative and complementary therapies for gliomas.

Conclusions:

  • Novel therapies, including immunotherapy and metabolic targeting, offer potential breakthroughs for glioma treatment.
  • Addressing tumor heterogeneity and blood-brain barrier challenges is crucial for therapeutic success.
  • Developing evidence-based approaches for novel and alternative therapies is essential for improving glioma patient outcomes.